LabCorp is Scheduled to Present at the 35th Annual J.P. Morgan Healthcare Conference
January 05 2017 - 8:45AM
Business Wire
Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:
LH) today announced it will participate at the 35th Annual J.P.
Morgan Healthcare Conference. LabCorp’s presentation is scheduled
for Tuesday, January 10, 2017 at 1:30 PM (PT).
A live audio webcast of the presentation will be available via
the Company website at www.labcorp.com and archived for replay.
About LabCorp®
Laboratory Corporation of America® Holdings (NYSE: LH),
an S&P 500 company, is the world’s leading healthcare
diagnostics company, providing comprehensive clinical laboratory
and end-to-end drug development services. With a mission to improve
health and improve lives, LabCorp delivers world-class diagnostic
solutions, brings innovative medicines to patients faster and
develops technology-enabled solutions to change the way care is
provided. With net revenue in excess of $8.5 billion in
2015, LabCorp’s 50,000 employees serve clients in 60 countries. To
learn more about LabCorp, visit www.labcorp.com, and to learn
more about Covance Drug Development, visit www.covance.com.
This press release contains forward-looking statements including
with respect to estimated 2016 guidance and the impact of various
factors on operating results. Each of the forward-looking
statements is subject to change based on various important factors,
including without limitation, competitive actions in the
marketplace, adverse actions of governmental and other third-party
payers and the results from the Company’s acquisition of Covance.
Actual results could differ materially from those suggested by
these forward-looking statements. Further information on potential
factors that could affect LabCorp’s operating and financial results
is included in the Company’s Form 10-K for the year ended December
31, 2015, and subsequent Forms 10-Q, including in each case under
the heading risk factors, and in the Company’s other filings with
the SEC, as well as in the risk factors included in Covance’s
filings with the SEC. The information in this press release should
be read in conjunction with a review of the Company’s filings with
the SEC including the information in the Company’s Form 10-K for
the year ended December 31, 2015, and subsequent Forms 10-Q, under
the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170105005364/en/
Laboratory Corporation of America®
HoldingsInvestorsScott Frommer,
336-436-5076Investor@labcorp.comorMediaPattie
Kushner, 336-436-8263Media@labcorp.comCompany
Information: www.labcorp.com
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Laboratory Corporation o... (NYSE:LH)
Historical Stock Chart
From Apr 2023 to Apr 2024